Low serum enterolactone concentration is associated with low colonic Lactobacillus-Enterococcus counts in men but is not affected by a synbiotic mixture in a randomised, placebo-controlled, double-blind, cross-over intervention study

British Journal of Nutrition

Volumn 111, Issue 2, 2014, Pages 301-309

  Holma, Reetta ^a   Kekkonen, Riina A ^b   Hatakka, Katja ^b   Poussa, Tuija ^c   Vapaatalo, Heikki ^a   Adlercreutz, Herman ^d   Korpela, Riitta ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b VALIO LTD   (Finland)

^c NOKIA RESEARCH CENTER   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Faecal microbiota; Sensitive C reactive protein; Serum enterolactone; Synbiotic mixture

Indexed keywords

C REACTIVE PROTEIN; ENTEROLACTONE; GALACTOSE OLIGOSACCHARIDE; PLACEBO; SENSITIVE C REACTIVE PROTEIN; SYNBIOTIC AGENT; UNCLASSIFIED DRUG; 2,3 BIS(3' HYDROXYBENZYL)BUTYROLACTONE; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; DRUG DERIVATIVE; GAMMA BUTYROLACTONE; LIGNAN; PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BLOOD LEVEL; COLONY FORMING UNIT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENTEROCOCCUS; FECES MICROFLORA; FEEDING BEHAVIOR; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LACTOBACILLUS; MALE; NONHUMAN; PATIENT COMPLIANCE; PROPIONIBACTERIUM; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SERUM ENTEROLACTONE CONCENTRATION; BLOOD; COLON; CONTROLLED CLINICAL TRIAL; FECES; INFORMATION PROCESSING; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT; BIFIDOBACTERIUM; CLINICAL ARTICLE; COLON FLORA; OUTCOME ASSESSMENT;

4-BUTYROLACTONE; ADULT; COLON; CROSS-OVER STUDIES; DATA COLLECTION; DOUBLE-BLIND METHOD; ENTEROCOCCUS; FECES; FOOD HABITS; HUMANS; LACTOBACILLUS; LIGNANS; MALE; MIDDLE AGED; SYNBIOTICS; YOUNG ADULT;

ENTEROCOCCUS; LACTOBACILLUS;

EID: 84896603954     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114513002420     Document Type: Article

References (38)

1. Vanharanta M, Voutilainen S, Lakka TA, et al. (1999) Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 354, 2112-2115.
2. Vanharanta M, Voutilainen S, Rissanen TH, et al. (2003) Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone-Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 163, 1099-1104.
3. Kitts DD, Yuan YV, Wijewickreme AN, et al. (1999) Antioxi-dant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 202, 91-100.
4. 2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis 160, 465-469.
5. Owen AJ, Roach PD & Abbey M (2004) Regulation of low-density lipoprotein receptor activity by estrogens and phytoestrogens in a HepG2 cell model. Ann Nutr Metab 48, 269-275.
6. Owen AJ & Abbey M (2004) The effect of estrogens and phy-toestrogenic lignans on macrophage uptake of atherogenic lipoproteins. Biofactors 20, 119-127.
7. Penttinen P, Jaehrling J, Damdimopoulos AE, et al. (2007) Diet-derived polyphenol metabolite enterolactone is a tissue-specific estrogen receptor activator. Endocrinology 148, 4875-4886.
8. Borriello SP, Setchell KDR, Axelson M, et al. (1985) Production and metabolism of lignans by the human faecal flora. J Appl Bacteriol 58, 37-43.
9. Heinonen S, Nurmi T, Liukkonen K, et al. (2001) In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 49, 3178-3186.
10. Peterson J, Dwyer J, Adlercreutz H, et al. (2010) Dietary lignans: physiology and potential for cardiovascular disease risk reduction. Nutr Rev 68, 571-603.
11. Adlercreutz H (2007) Lignans and human health. Crit Rev Clin Lab Sci 44, 483-525.
12. Clavel T, Doré J & Blaut M (2006) Bioavailability of lignans in human subjects. Nutr Res Rev 19, 187-196.
13. Rowland I, Faughnan M, Hoey L, et al. (2003) Bioavailability of phyto-oestrogens. Br J Nutr 89, Suppl. 1, S45-S58.
14. Clavel T, Henderson G, Engst W, et al. (2006) Phylogeny of human intestinal bacteria that activate the dietary lignan secoi-solariciresinol diglucoside. FEMS Microbiol Ecol 55, 471-478.
15. Kilkkinen A, Pietinen P, Klaukka T, et al. (2002) Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 155, 472-477.
16. Ridker PM (2007) C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49, 2129-2138.
17. Tiihonen K, Ouwehand AC & Rautonen N (2010) Effect of overweight on gastrointestinal microbiology and immunology: correlation with blood biomarkers. Br J Nutr 103, 1070-1078.
18. Brignardello J, Morales P, Diaz E, et al. (2010) Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther 32, 1307-1314.
19. Tzounis X, Rodriguez-Mateos A, Vulevic J, et al. (2011) Pre-biotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr 93, 62-72.
20. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, et al. (2004) Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 93, 97-108.
21. Sanderson IR (2007) Dietary modulation of GALT. J Nutr 137, Suppl. 11, 2557S-2562S.
22. Seifert S & Watzl B (2007) Inulin and oligofructose: review of experimental data on immune modulation. J Nutr 137, Suppl. 11, 2563S-2567S.
23. Kekkonen RA, Holma R, Hatakka K, et al. (2011) A probiotic mixture including galactooligosaccharides decreases fecal b-glucosidase activity but does not affect serum enterolac-tone concentration in men during a two-week intervention. J Nutr 141, 870-876.
24. Adlercreutz H, Wang GJ, Lapcik O, et al. (1998) Time resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem 265, 208-215.
25. Stumpf K, Uehara M, Nurmi T, et al. (2000) Changes in the time-resolved fluoroimmunoassay of plasma enterolactone. Anal Biochem 284, 153-157.
26. Myllyluoma E, Ahlroos T, Veijola L, et al. (2007) Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. Int J Antimicrob Agents 29, 66-72.
27. Xie LH, Akao T, Hamasaki K, et al. (2003) Biotransfor-mation of pinoresinol diglucoside to mammalian lignans by human intestinal microflora, and isolation of Enterococcus faecalis strain PDG-1 responsible for the transformation of (+)-pinoresinol to (+)-lariciresinol. Chem Pharm Bull (Tokyo) 51, 508-515.
28. Mroczyńska M & Libudzisz Z (2010) Beta-glucuronidase and beta-glucosidase activity of Lactobacillus and Enterococcus isolated from human feces. Pol J Microbiol 59, 265-269.
29. Costabile A, Klinder A, Fava F, et al. (2008) Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. Br J Nutr 99, 110-120.
30. Kilkkinen A, Stumpf K, Pietinen P, et al. (2001) Determinants of serum enterolactone concentration. Am J Clin Nutr 73, 1094-1100.
31. Khalif IL, Quigley EM, Konovitch EA, et al. (2005) Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 37, 838-849.
32. Nettleton JA, Greany KA, Thomas W, et al. (2004) Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer. J Nutr 134, 1998-2003.
33. Kajander K, Krogius-kurikka L, Rinttilä T, et al. (2007) Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther 26, 463-473.
34. Stumpf K, Pietinen P, Puska P, et al. (2000) Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland. Cancer Epidemiol Biomarkers Prev 9, 1369-1372.
35. Jacobs DR, Pereira MA, Stumpf K, et al. (2002) Whole grain food intake elevates serum enterolactone. Br J Nutr 88, 111-116.
36. Nova E, Viadel B, Wärnberg J, et al. (2011) Beneficial effects of a synbiotic supplement on self-perceived gastrointestinal well-being and immunoinflammatory status of healthy adults. J Med Food 14, 79-85.
37. Marschan E, Kuitunen M, Kukkonen K, et al. (2008) Pro-biotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 38, 611-618.
38. Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 27, 48-57.